Abstract
Background and study aim : Hepatitis B is a serious and common infectious disease of the liver, affecting millions of peoplethroughout the world. In this regard, Egypt has an intermediate HBV seroprevalence. Quantitation of hepatitis B surface antigen (HBsAg) by automated chemiluminescent micro-particle immunoassay has been proposed to be a surrogate marker. The aim of this study was to evaluate correlation between HBsAg quantitation assay, histo-pathology and viral-DNA level in chronic hepatitis BeAg negative patients. Patients and methods: This study carried on 50 HBV-DNA positive naive CHB patients. All the studied patients wereHBeAg negative. HBV DNA was measured by real-time polymerase chain reaction, and serum HBsAg was quantified by electrochemiluminescence assay (Roche Diagnostic). Liver biopsy done to all patients in this study for histopathological grading and staging of hepatic fibrosis by experienced pathologist using METAVER scoring. Results: A significant correlation between serum HBsAg quantitation level and HBV DNA levels was revealed in all studied HBeAg negative patients (r =0.748, P= 0.05). Conclusion: All the studied patients were tested for assess correlation between HBsAg quantitation, HBV-DNA level and histo-pathology grading and staging. There is strong positive correlation between HBsAg quantation level and HBV-DNA and between HBsAg quantation level and stages of fibrosis. No correlation between HBV DNA levels and histopathology.
Highlights
One third of the world's population has serological evidence of past or present infection with HBV and 350-400 million people are chronic HBV surface antigen (HBsAg) carrier [1].Clinical course of chronic hepatitis B (CHB) is highly variable, ranging from an asymptomatic carrier state, to the development of cirrhosis, hepatic decompensation and hepatocellular carcinoma (HCC) [2].The prevalence of chronic hepatitis B virus infection is about 5% worldwide, but it differs between regions, 0.1%02.0% in the United States and western Europe, 2.0%- 8.0% in Mediterranean countries and Japan, and 8.0%-20% in southeast Asia and Sub-Saharan regions [3].Egypt has an intermediate HBV seroprevalence
A significant correlation between serum HBsAg quantitation level and HBV DNA levels was revealed in all studied HBeAg negative patients (r =0.748, P=
There is no significant correlation between serum HBsAg quantitation level and activity by Metaver scoring in all studied patients (P >0.05)
Summary
One third of the world's population has serological evidence of past or present infection with HBV and 350-400 million people are chronic HBV surface antigen (HBsAg) carrier [1]. Limited data are available about HBV genotyping among Egyptian blood donors, in Upper Egypt [4]. Hepatitis B is a serious and common infectious disease of the liver, affecting millions of people throughout the world. In this regard, Egypt has an intermediate HBV seroprevalence. Quantitation of hepatitis B surface antigen (HBsAg) by automated chemiluminescent micro-particle immunoassay has been proposed to be a surrogate marker. The aim of this study was to evaluate correlation between HBsAg quantitation assay, histopathology and viral-DNA level in chronic hepatitis BeAg negative patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
